BOAN BIOTECH (06955) has issued a profit warning, announcing that the Group expects to record a net loss attributable to equity holders of the company of approximately RMB 79 million to RMB 89 million for the six months ended June 30, 2026 (the Reporting Period). This compares to a net profit attributable to equity holders of the company of approximately RMB 21 million for the six months ended June 30, 2025.

The Board believes the Group's swing from profit to loss during the Reporting Period is primarily due to increased research and development expenses resulting from the acceleration of the Group's innovation strategy. Several of the Group's drug candidates have advanced into clinical trials and critical preclinical studies, including BA1106 (anti-CD25 monoclonal antibody), BA1302 (CD228-targeting ADC), BA1203 (PD-1/IL-2 antibody cytokine prodrug), BA2201 (TL1A/IL-23p19 bispecific antibody), and BA1304 (EGFR/B7-H3 bispecific antibody ADC). Consequently, clinical trial expenses and research and development costs for these projects have significantly increased during the Reporting Period.